{
    "ticker": "RGEN",
    "name": "Repligen Corporation",
    "description": "Repligen Corporation is a leading global supplier of bioprocessing technologies and solutions for the biopharmaceutical industry. Founded in 1981, Repligen is committed to supporting the development and manufacturing of biologics, including monoclonal antibodies and gene and cell therapies. The company specializes in high-performance protein purification and a range of bioprocessing technologies that enhance the efficiency and effectiveness of biomanufacturing processes. Repligen\u2019s product portfolio includes innovative solutions such as XCell ATF\u00ae for cell retention, OPUS\u00ae single-use chromatography columns, and various filtration systems. The company focuses on continuous innovation and has established itself as a trusted partner for biopharmaceutical companies worldwide. With a dedication to sustainability and operational excellence, Repligen is also expanding its global footprint through strategic acquisitions and investments in advanced technologies. The company strives to improve patient outcomes by enabling the efficient production of life-saving therapies while maintaining a commitment to quality and regulatory compliance. Repligen\u2019s mission is to empower biopharmaceutical manufacturers to bring new therapies to market faster and more efficiently, ultimately enhancing the health and well-being of patients globally.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Waltham, Massachusetts, USA",
    "founded": "1981",
    "website": "https://www.repligen.com",
    "ceo": "Tony Hunt",
    "social_media": {
        "twitter": "https://twitter.com/Repligen",
        "linkedin": "https://www.linkedin.com/company/repligen/"
    },
    "investor_relations": "https://investors.repligen.com",
    "key_executives": [
        {
            "name": "Tony Hunt",
            "position": "CEO"
        },
        {
            "name": "James Thomas",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Protein Purification",
            "products": [
                "XCell ATF\u00ae",
                "OPUS\u00ae Columns"
            ]
        },
        {
            "category": "Filtration Solutions",
            "products": [
                "Kits and Systems"
            ]
        }
    ],
    "seo": {
        "meta_title": "Repligen Corporation | Bioprocessing Technologies for Biopharmaceuticals",
        "meta_description": "Explore Repligen Corporation, a leader in bioprocessing technologies for the biopharmaceutical industry. Learn about our innovative solutions and commitment to improving patient outcomes.",
        "keywords": [
            "Repligen",
            "Biotechnology",
            "Biopharmaceuticals",
            "Protein Purification",
            "XCell ATF",
            "OPUS Columns"
        ]
    },
    "faq": [
        {
            "question": "What does Repligen specialize in?",
            "answer": "Repligen specializes in bioprocessing technologies and solutions for the biopharmaceutical industry."
        },
        {
            "question": "Who is the CEO of Repligen?",
            "answer": "Tony Hunt is the CEO of Repligen Corporation."
        },
        {
            "question": "Where is Repligen headquartered?",
            "answer": "Repligen is headquartered in Waltham, Massachusetts, USA."
        },
        {
            "question": "What are some of Repligen's main products?",
            "answer": "Repligen's main products include XCell ATF\u00ae and OPUS\u00ae single-use chromatography columns."
        },
        {
            "question": "When was Repligen founded?",
            "answer": "Repligen was founded in 1981."
        }
    ],
    "competitors": [
        "PFE",
        "AMGN",
        "GILD",
        "BMY"
    ],
    "related_stocks": [
        "ABBV",
        "JNJ",
        "REGN",
        "MRNA"
    ]
}